LEXICON PHARMACEUTICAL

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

27 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

10 Sep 2024 07:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

03 Sep 2024 15:00:00 By Nasdaq GlobeNewswire

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

03 Sep 2024 07:00:01 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista

21 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

13 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

01 Aug 2024 15:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

16 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure

15 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

08 Jul 2024 08:15:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

21 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

19 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

29 May 2024 06:30:00 By Nasdaq GlobeNewswire

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

14 May 2024 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

09 May 2024 06:30:00 By Nasdaq GlobeNewswire